SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT polarityte, inc.Warrant Agreement • December 23rd, 2020 • Polarityte, Inc. • Biological products, (no disgnostic substances)
THIS SERIES B PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ________________________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from PolarityTE, Inc., a Delaware corporation (the “Company”), up to 5,238,043 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT polarityte, inc.Placement Agent Common Stock Purchase Warrant • December 23rd, 2020 • Polarityte, Inc. • Biological products, (no disgnostic substances)
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 21, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from PolarityTE, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of November 6, 2020, as amended on December 16, 2020.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 23rd, 2020 • Polarityte, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 21, 2020, between PolarityTE, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the signature page hereto, including its successors and assigns (the “Purchaser”)
